个人介绍 学术任职 学术论着 专家风采
博士，主管药师。主要从事血栓相关疾病的机制研究与创新药物开发。相关研究成果以第一作者身份在Clinical translational medcine、Pharmacotherapy等高水平SCI杂志，授权国内发明专利5项。承担国家自然科学基金项目1项、timi天美传孟若羽院级科研项目2项。
(1) Qian Xiang; Zhe Wang (co-first author); Guangyan Mu, et al; Genetic variants influenced the risk of bleeding and pharmacodynamics of rivaroxaban in patients with nonvalvular atrial fibrillation: A multicentre prospective cohort study, Clinical translational medicine, 2023, 13(5): e1263
(2) Qian Xiang; Zhe Wang(co-first author) ; Guangyan Mu; et al; PROK2, HRNR, and FIG4 as potential genetic biomarkers of high bleeding propensity in East Asian patients with Drug Therapy, 2022, 42(12): 872-879
(3) Zhe Wang ; Qian Xiang; Zhiyan Liu, et al; Genetic polymorphisms of TMEM51 influenced the risk of bleeding by ticagrelor pharmacodynamics, the 19th World Congress of Basic & Clinical Pharmacology 2023, Glasgow, 2023-7-2至2023-7-7
(4)Zhe Wang; Qiufen Xie; Qian Xiang; et al;Predictive value of methods measuring platelet activation for ischemic events in patients receiving clopidogrel: a systematic review and meta-analysis, Current Pharmaceutical Design, 2019, 24(44): 5313-5333
(5)Zhe Wang; Qian Xiang; Kun Hu; et al;Comparison of the safety and efficacy of direct oral anticoagulants and warfarin in atrial fibrillation or venous thromboembolism in patients with renal impairment: systematic review, meta-analysis and network meta-analysis., American Journal of Cardiovascular Drugs, 2021.11,21(6): 643-657
北京市西城区西什库大街8号
100034
83572211